To answer your question 'deren', this stock on the one hand is...

To answer your question 'deren', this stock on the one hand is similar to other new technology stocks in that it was ridden originally on speculation and buzz of potential future worth (but not very well articulated by management who consistently missed the point of exciting the market and selling to the full the potential of the stock at every opportunity) ... But on the other hand, there are still many share holders holding onto their shares that do see the strategy coming together and the right partnerships being formed in a new but proven emerging health market (despite clunking leadership to date).... Think Ferrari 458 given to an L-plater, but new experienced driver just about to step in.

Slow trickle of shares at the moment is due to the upcoming merger/conversion to Mach7 shares (see announcements) and possibly still some check outs from when originally a lot of the shares were bought or allocated early on around at the 5-6 cents mark ....or perhaps the slow drag just testing patience of smaller investors that may want to spin the wheel elsewhere rather than go stale here waiting for the correction to a more realistic share price as is expected by some.

Based on the revenues already being realised by Mach7, and the potential growth here I think I'll be holding on.
Expecting to see 12-15 cents under the new name that has exposure in the US in my opinion.